A University of Florida team exposed young and old mice to cannabis smoke for a month and found that aging itself drives broad increases in inflammatory signaling across blood and brain, while cannabis smoke produced a striking, region-specific split: in the hippocampus it pushed inflammatory markers down in old mice but up in young mice. The drug effects were essentially confined to the hippocampus, not the blood or prefrontal cortex.
Inflammation that smolders quietly for decades is one of the leading suspects behind brain aging. Scientists call it “inflammaging,” and it tracks with memory decline and neurodegenerative disease. Cannabis, meanwhile, is increasingly used by older adults for pain, sleep, anxiety and Parkinson’s symptoms, and cannabinoids have a reputation as anti-inflammatory agents. But almost all of that reputation was built on cell cultures, disease models, and young animals dosed by injection. Nobody had carefully asked what realistic, inhaled cannabis actually does to inflammation in an old brain.
A group at the University of Florida set out to fill that gap. They took 40 mice, half young (4 months) and half aged (22 months, roughly equivalent to a person in their late 60s), and piped them smoke from real cannabis cigarettes (about 6% THC) or placebo cigarettes every day for 30 days using an automated smoking machine. Then they measured dozens of inflammatory proteins in serum, the prefrontal cortex, and the hippocampus.
The first finding was blunt and consistent: old age inflamed everything. Across all three tissues, aged mice showed elevated cytokines, with some of the largest age effects seen for P-Selectin, platelet factor 4, and Galectin-3 in brain tissue. These were not subtle shifts; several were among the largest effect sizes you will see in a biology paper.
The more interesting story was the cannabis effect, and its central twist. In blood and prefrontal cortex, cannabis did little or modestly nudged inflammation upward. But in the hippocampus, the memory hub, the drug acted like a dimmer switch wired backwards depending on age. In old mice, cannabis smoke lowered two markers tied to brain aging, IL-13 and Dkk1, effectively reversing their age-related rise. In young mice, the very same exposure raised them. This bidirectional pattern mirrors a recurring observation in the field: low-dose THC tends to help old rodent brains and impair young ones. The authors stop well short of endorsing cannabis for healthy aging; rather, they have flagged specific molecules worth chasing.
Actionable Insights
Be cautious: this is a 30-day mouse study with no behavioral or lifespan outcomes, so practical take-homes are limited and provisional.
The single most robust, real-world message is about aging itself, not cannabis. The age signal was enormous. Hippocampal P-Selectin separated young from old with a standardized effect size of roughly Cohen’s d = 2.1 (partial eta-squared about 0.52, meaning age alone explained over half the variance), platelet factor 4 d = 2.0, and prefrontal Galectin-3 d = 1.9. For context, a d of 0.8 is already considered “large.” These are markers of vascular, platelet, and microglial inflammaging, and they reinforce that interventions targeting low-grade inflammation (exercise, metabolic health, sleep) plausibly target a dominant axis of brain aging. [Confidence: High]
On cannabis specifically, the honest take-home is restraint. The hippocampal “anti-inflammatory” reversal in old mice (IL-13 and Dkk1, interaction d roughly 1.4–1.5) is real but narrow, did not appear in blood or cortex, and was driven by inhaled combustion smoke, not a clean compound. The same exposure was net pro-inflammatory in young brains. Translation: there is no basis here for a young or healthy person to use cannabis as an anti-inflammatory longevity tool, and even for older users the effect is region-specific and unproven for cognition.
Source:
-
Paywalled Paper: Effects of sub-chronic cannabis smoke exposure on inflammatory markers
in serum and brain in younger and older mice - Institution: University of Florida (Departments of Neuroscience and Psychiatry; Center for Cognitive Aging and Memory; Center for Addiction Research), Gainesville, Florida.
- Country: United States.
- Journal: Neurobiology of Aging (Elsevier), Volume 166, 2026, pages 58–68. DOI: 10.1016/j.neurobiolaging.2026.05.008.
- Impact Evaluation: CiteScore is 8.2 (Scopus) and the Journal Impact Factor is approximately 3.3 (JCR 2024); the journal sits in Q1 of its specialty. The impact score of this journal is 8.2 (CiteScore; JIF ~3.3), evaluated against a typical high-end range of 0–60+ for top general-science and elite specialty journals, therefore this is a Medium impact journal.